Dordaviprone
Malignant Epithelial Tumor Of Ovary
Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
Ira Winer
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
30Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04055649CT.gov ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Epithelial Tumor Of Ovary
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dordaviprone (this asset) | Ira Winer | P2 | CC · 45 |
| Carboplatin | Wake Forest University Health Sciences | P2 | BB |
| Niraparib | CanariaBio Inc. | P2 | CCC |
| Adriamycin | National Cheng-Kung University Hospital | P1/2 | CCC |
| Trientine | National Cheng-Kung University Hospital | P1/2 | CCC |
| Avelumab | University of Texas Southwestern Medical Center | P2 | CCC |
| Oregovamab | CanariaBio Inc. | P2 | CC |
Other indications for Dordaviprone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Glioblastoma | — | P2 | CCC · 48 |
| Triple-Negative Breast Carcinoma | — | P2 | CC · 47 |
| Endometrial Carcinoma | — | P2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Dordaviprone in Malignant Epithelial Tumor Of Ovary. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/dordaviprone-malignant-epithelial-tumor-of-ovary
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →